Literature DB >> 6556194

Human plasma kallikrein releases neutrophil elastase during blood coagulation.

Y T Wachtfogel, U Kucich, H L James, C F Scott, M Schapira, M Zimmerman, A B Cohen, R W Colman.   

Abstract

Elastase is released from human neutrophils during the early events of blood coagulation. Human plasma kallikrein has been shown to stimulate neutrophil chemotaxis, aggregation, and oxygen consumption. Therefore, the ability of kallikrein to release neutrophil elastase was investigated. Neutrophils were isolated by dextran sedimentation, and elastase release was measured by both an enzyme-linked immunosorbent assay, and an enzymatic assay using t-butoxy-carbonyl-Ala-Ala-Pro-Val-amino methyl coumarin as the substrate. Kallikrein, 0.1-1.0 U/ml, (0.045-0.45 microM), was incubated with neutrophils that were preincubated with cytochalasin B (5 micrograms/ml). The release of elastase was found to be proportional to the kallikrein concentration. Kallikrein released a maximum of 34% of the total elastase content, as measured by solubilizing the neutrophils in the nonionic detergent Triton X-100. A series of experiments was carried out to determine if kallikrein was a major enzyme involved in neutrophil elastase release during blood coagulation. When 10 million neutrophils were incubated in 1 ml of normal plasma in the presence of 30 mM CaCl2 for 90 min, 2.75 micrograms of elastase was released. In contrast, neutrophils incubated in prekallikrein-deficient or Factor XII-deficient plasma released less than half of the elastase, as compared with normal plasma. The addition of purified prekallikrein to prekallikrein-deficient plasma restored neutrophil elastase release to normal levels. Moreover, release of elastase was enhanced in plasma deficient in C1-inhibitor, the major plasma inhibitor of kallikrein. This release was not dependent upon further steps in the coagulation pathway, or on C5a, since levels of elastase, released in Factor XI- or C5-deficient plasma, were similar to that in normal plasma, and an antibody to C5 failed to inhibit elastase release. These data suggest that kallikrein may be a major enzyme responsible for the release of elastase during blood coagulation.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6556194      PMCID: PMC370455          DOI: 10.1172/JCI111126

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  22 in total

1.  Mechanisms of lysosomal enzyme release from human leukocytes: microtubule assembly and membrane fusion induced by a component of complement.

Authors:  I Goldstein; S Hoffstein; J Gallin; G Weissmann
Journal:  Proc Natl Acad Sci U S A       Date:  1973-10       Impact factor: 11.205

2.  Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g.

Authors:  A Böyum
Journal:  Scand J Clin Lab Invest Suppl       Date:  1968

3.  Plasma kallikrein and Hageman factor in Gram-negative bacteremia.

Authors:  J W Mason; U Kleeberg; P Dolan; R W Colman
Journal:  Ann Intern Med       Date:  1970-10       Impact factor: 25.391

4.  Human leukocyte granule elastase: rapid isolation and characterization.

Authors:  R J Baugh; J Travis
Journal:  Biochemistry       Date:  1976-02-24       Impact factor: 3.162

5.  Stimulation of human neutrophil leukocyte aerobic glucose metabolism by purified chemotactic factors.

Authors:  E J Goetzl; K F Austen
Journal:  J Clin Invest       Date:  1974-02       Impact factor: 14.808

6.  Cytochalasin B: effect on lysosomal enzyme release from human leukocytes.

Authors:  R B Zurier; S Hoffstein; G Weissmann
Journal:  Proc Natl Acad Sci U S A       Date:  1973-03       Impact factor: 11.205

7.  The sequential release of granule constitutents from human neutrophils.

Authors:  B J Bentwood; P M Henson
Journal:  J Immunol       Date:  1980-02       Impact factor: 5.422

8.  Experimental emphysema induced with purified human neutrophil elastase: tissue localization of the instilled protease.

Authors:  A Janoff; B Sloan; G Weinbaum; V Damiano; R A Sandhaus; J Elias; P Kimbel
Journal:  Am Rev Respir Dis       Date:  1977-03

9.  A prealbumin activator of prekallikrein. 3. Appearance of chemotactic activity for human neutrophils by the conversion of human prekallikrein to kallikrein.

Authors:  A P Kaplan; A B Kay; K F Austen
Journal:  J Exp Med       Date:  1972-01       Impact factor: 14.307

10.  Mechanisms of activation of C'1 esterase in hereditary angioneurotic edema plasma in vitro.

Authors:  V H Donaldson
Journal:  J Exp Med       Date:  1968-03-01       Impact factor: 14.307

View more
  44 in total

Review 1.  Kallikreins and kinins: mediators in inflammatory joint disease?

Authors:  K Worthy; C D Figueroa; P A Dieppe; K D Bhoola
Journal:  Int J Exp Pathol       Date:  1990-08       Impact factor: 1.925

2.  Kallikrein-kininogen system activation and bradykinin (B2) receptors in indomethacin induced enterocolitis in genetically susceptible Lewis rats.

Authors:  A Stadnicki; R B Sartor; R Janardham; I Stadnicka; A A Adam; C Blais; R W Colman
Journal:  Gut       Date:  1998-09       Impact factor: 23.059

Review 3.  The plasma kallikrein-kinin system in sepsis, inflammatory arthritis, and enterocolitis.

Authors:  R W Colman; R B Sartor; A A Adam; R A DeLa Cadena; A Stadnicki
Journal:  Clin Rev Allergy Immunol       Date:  1998       Impact factor: 8.667

4.  Activation of plasma contact and coagulation systems and neutrophils in the active phase of ulcerative colitis.

Authors:  A Stadnicki; M Gonciarz; T J Niewiarowski; J Hartleb; M Rudnicki; N B Merrell; R A Dela Cadena; R W Colman
Journal:  Dig Dis Sci       Date:  1997-11       Impact factor: 3.199

5.  Local abnormalities in coagulation and fibrinolytic pathways predispose to alveolar fibrin deposition in the adult respiratory distress syndrome.

Authors:  S Idell; K K James; E G Levin; B S Schwartz; N Manchanda; R J Maunder; T R Martin; J McLarty; D S Fair
Journal:  J Clin Invest       Date:  1989-08       Impact factor: 14.808

6.  A monoclonal antibody to high-molecular weight kininogen is therapeutic in a rodent model of reactive arthritis.

Authors:  Ricardo G Espinola; Audrey Uknis; Irma M Sainz; Irma Isordia-Salas; Robin Pixley; Raul DeLa Cadena; Walter Long; Alexis Agelan; John Gaughan; Albert Adam; Robert W Colman
Journal:  Am J Pathol       Date:  2004-09       Impact factor: 4.307

7.  Proteolytic inactivation of plasma C1- inhibitor in sepsis.

Authors:  J H Nuijens; A J Eerenberg-Belmer; C C Huijbregts; W O Schreuder; R J Felt-Bersma; J J Abbink; L G Thijs; C E Hack
Journal:  J Clin Invest       Date:  1989-08       Impact factor: 14.808

8.  Factor XII and uPAR upregulate neutrophil functions to influence wound healing.

Authors:  Evi X Stavrou; Chao Fang; Kara L Bane; Andy T Long; Clément Naudin; Erdem Kucukal; Agharnan Gandhi; Adina Brett-Morris; Michele M Mumaw; Sudeh Izadmehr; Alona Merkulova; Cindy C Reynolds; Omar Alhalabi; Lalitha Nayak; Wen-Mei Yu; Cheng-Kui Qu; Howard J Meyerson; George R Dubyak; Umut A Gurkan; Marvin T Nieman; Anirban Sen Gupta; Thomas Renné; Alvin H Schmaier
Journal:  J Clin Invest       Date:  2018-01-29       Impact factor: 14.808

9.  Administration of C1 inhibitor reduces neutrophil activation in patients with sepsis.

Authors:  Sacha Zeerleder; Christoph Caliezi; Gerard van Mierlo; Anke Eerenberg-Belmer; Irmela Sulzer; C Erik Hack; Walter A Wuillemin
Journal:  Clin Diagn Lab Immunol       Date:  2003-07

10.  Upregulation of prolylcarboxypeptidase (PRCP) in lipopolysaccharide (LPS) treated endothelium promotes inflammation.

Authors:  My-Linh Ngo; Fakhri Mahdi; Dhaval Kolte; Zia Shariat-Madar
Journal:  J Inflamm (Lond)       Date:  2009-01-27       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.